Jardimet
Generic Name: Empagliflozin
Dosage Form: Tablet
TG Name: Endocrine & Diabetes
1. What is Jardimet®?
Jardimet® is a combination of Empagliflozin, a Sodium-glucose cotransporter-2 (SGLT2) inhibitor and Metformin Hydrochloride, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Metformin Hydrochloride is appropriate.
2. How Jardimet® works in our body?
Jardimet® combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a member of the biguanide class.
Empagliflozin:
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin hydrochloride:
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
3. What is the indication of Jardimet®?
Jardimet® is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin.
4. What are the dosage and administration of Jardimet®?
Individualize starting dose based on the patient’s current drug regimen.
Jardimet® 5/500 is indicated to take twice daily with meals, with gradual dose escalation to reduce the GI adverse effects due to Metformin. Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of Metformin Hydrochloride 2000 mg and Empagliflozin 25 mg.
5. What are the contraindications of Jardimet®?
It is contraindicated in patients with moderate to severe renal impairment (eGFR less than 45 mL/min/1.73 m2), end stage renal disease, or dialysis.
Acute or chronic metabolic acidosis, including diabetic ketoacidosis or type 1 diabetes mellitus. Diabetic ketoacidosis should be treated with insulin. History of serious hypersensitivity reaction to Empagliflozin and Metformin Hydrochloride.
6. What are the adverse effects of Jardimet®?
Adverse effects of Jardimet® may include low blood sugar (hypoglycemia), urinary tract infection, increased urination, genital yeast infections, diarrhea, nausea, vomiting, gas, abdominal discomfort, indigestion, weakness or lack of energy, high cholesterol, joint pain, and headache.
7. In which condition Jardimet® should be stored?
Keep in a dry place, below 30° C. Protect from light and keep out of the reach of children.
